The UK’s first fully-licensed EU-GMP medical cannabis cultivation facility has opened its doors to doctors, as its first products were made available on prescription for patients earlier this month. After five years and over £10 million in investment, Dalgety has become the first facility in the [...]
Since the legalisation of medical cannabis in the UK in 2018, its integration into mainstream healthcare has faced significant hurdles. While private clinics have provided access to cannabis-based medicines (CBMPs), many healthcare professionals remain sceptical, largely due to outdated perceptions, limited clinical education, and a lack [...]
A new research partnership between the University of Malta and the Authority for the Responsible Use of Cannabis will study the differences between illegal cannabis and that which is accessed through licensed associations. The agreement, which will see the University of Malta and the ARUC collaborate [...]
Europe’s first patient-led event will return next month with a focus on the medicinal use of cannabis in chronic neurodegenerative diseases. Following a successful launch in Madrid in October, We, The Patients, will host its first event in Switzerland on 1 March at the Resident Zürich [...]
What is the Care Quality Commission (CQC)? The Care Quality Commission (CQC) is the UK’s independent regulator of health and social care services. It exists to ensure that clinics, hospitals, and other healthcare providers are following all relevant guidelines and meet essential standards of safety, effectiveness, [...]
Via Business of Cannabis Spain’s long-awaited medical cannabis program has finally taken a step forward as a draft of a Royal Decree has been sent to the European Union for approval. If approved, this should give Spanish patients legal access to medical cannabis for the first [...]
Written by: Releaf’s Clinical Dr Alex Van Heerden After years prescribing opioids, Dr Alexander Van Heerden, a clinical doctor at Releaf with a background in emergency medicine, believes medical cannabis should be considered a first-line treatment option rather than an alternative. The Opioid Crisis: Over 500,000 [...]
New findings, from the largest study of its kind, suggest cannabis use may be linked to a decline in working memory among young adults. The new study published in JAMA Network Open explores the effects of both recent and lifetime cannabis use on brain function during [...]
Tetrahydrocannabinolic acid (THCa) is a non-psychoactive cannabinoid found abundantly in raw cannabis plants. Unlike its decarboxylated form, tetrahydrocannabinol (THC), THCa does not produce intoxicating effects. This distinction is crucial for medical cannabis patients, healthcare professionals, and industry experts seeking to understand the therapeutic potential and legal considerations of THCa, particularly within the United Kingdom. Biochemical Nature of THCa THCa serves as the acidic precursor to THC. In its natural state, cannabis plants synthesise cannabinoids in their acidic forms, with THCa being predominant. When exposed to heat through processes like smoking, vaping, or cooking—a reaction known as decarboxylation—THCa loses a carboxyl group, transforming into THC, the compound responsible for cannabis’s psychoactive effects. Therapeutic Potential of THCa Emerging research suggests that THCa may offer several health benefits: Psychoactivity of THCa In its raw form, THCa is non-psychoactive and does not produce the “high” associated with THC consumption. This non-intoxicating nature makes it an attractive option for patients seeking therapeutic benefits without cognitive impairment. However, it’s essential to note that when THCa is heated, it converts into THC, thereby gaining psychoactive properties. Applications of THCa Given its potential therapeutic properties and non-psychoactive nature, THCa is utilised in various forms: Legal Status of THCa in the UK The Advisory Council on the Misuse of Drugs (ACMD) has provided insights into the behaviour and control status of tetrahydrocannabinolic acid (THCa) in its report on consumer cannabidiol (CBD) products. The report highlights that THCa does not significantly convert to Δ9-tetrahydrocannabinol (Δ9-THC) within the human body after ingestion. Additionally, while THCa can decarboxylate into Δ9-THC at temperatures below 100°C, this process requires prolonged exposure; at room temperature, the conversion is negligible. These findings suggest that THCa’s limited potential for in vivo conversion to psychoactive Δ9-THC may influence its regulatory status. The legal framework surrounding THCa in the United Kingdom is complex. While THCa itself is non-psychoactive, it is closely regulated due to its potential to convert into THC when heated. This conversion raises concerns for law enforcement and regulatory bodies. According to the UK’s Misuse of Drugs Regulations 2001, THC is a controlled substance, and any product containing cannabinoids that can be converted into THC may fall under this regulation. In practice, this means that while THCa is not explicitly listed as a controlled substance, its presence in products intended for consumption could be subject to legal scrutiny, especially if there’s a likelihood of decarboxylation into THC. Therefore, products containing THCa are subject to stricter controls and are generally less accessible than CBD products. In the United Kingdom, cannabis and its derivatives are primarily regulated under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001. Cannabis is classified as a Class B controlled drug, making it unlawful to possess, supply, produce, import, or export without appropriate licensing. The legislation defines cannabis to include any part of the plant, excluding mature stalks, fibre, and seeds. Additionally, cannabinoids such as THC are specifically controlled substances. While cannabidiol (CBD) in its pure form is not controlled, products containing other cannabinoids, including THCa, are subject to regulation. The Home Office acknowledges that due to challenges in isolating CBD from other cannabinoids, consumer CBD products may contain varying amounts of controlled substances like THC and THCa. Therefore, any product containing controlled cannabinoids is classified as a Class B controlled drug unless it meets the “exempt product” criteria outlined in Regulation 2 of the Misuse of Drugs Regulations 2001. Exempt Product Criteria For a product to be considered exempt, it must fulfil specific conditions: If a product meets all these criteria, it is not subject to the prohibitions on importation, exportation, production, supply, and possession under the Misuse of Drugs Act 1971. Conclusion THCa represents a promising cannabinoid with potential therapeutic benefits for various medical conditions. Its non-psychoactive nature makes it suitable for patients seeking relief without the intoxicating effects of THC. The sale and distribution of THCa products in the UK occupy a legally ambiguous space. While businesses continue their operations, the potential for legal challenges remains due to the intricate regulatory framework governing cannabis and its derivatives. It is imperative for businesses and consumers to stay informed and consult legal experts when navigating this evolving landscape. References Drug Licensing Factsheet (Cannabis, CBD & Other Cannabinoids) Consumer CBD products report – ACMD Is THCa legal in the UK – r/LegalAdviceUK – Reddit The Legal Weed No One’s Talking About – Vice Disclaimer The information provided in this article is intended for educational and informational purposes only and should not be construed as legal or medical advice. While efforts have been made to ensure the accuracy of the content, however the legal framework surrounding THCa is complex and subject to change. Readers are advised to consult with qualified legal professionals to obtain guidance tailored to their specific circumstances. The authors and publishers disclaim any liability arising from the use or misuse of the information contained herein.
The post THCa is it legal? first appeared on PatientsCann UK.
Via Business of Cannabis The first parliamentary debate on medical cannabis in the UK under the new Labour administration has shattered hopes of a more progressive stance on reform. Despite impassioned speeches from members of various parties, unanimously calling for the UK’s ‘patchwork’ cannabis regulation to [...]
Since the legalisation of medical cannabis in the UK in 2018, patients have faced numerous challenges in accessing and utilising cannabis-based medicinal products (CBMPs). Despite legal provisions, the landscape remains fraught with limited support, societal stigma, and complex legal hurdles. Organisations like Seed Our Future play a crucial role in advocating for patients’ rights and providing necessary support. Challenges in Legal Support The legal framework surrounding medical cannabis in the UK is complex, creating numerous obstacles for patients seeking treatment. While specialist doctors are legally permitted to prescribe cannabis-based medicinal products (CBMPs), access remains severely limited, forcing many patients to navigate a difficult and often expensive system. One of the primary challenges is the scarcity of NHS prescriptions for medical cannabis. Despite its legal status, NHS doctors rarely prescribe CBMPs, leaving most patients with no choice but to turn to private clinics. However, private prescriptions can be prohibitively expensive, making access to medical cannabis a privilege rather than a right for many who need it. Legal uncertainties further complicate matters. Many patients struggle to understand the exact legalities surrounding the possession and use of their prescribed cannabis, particularly in public spaces or workplaces. Questions about where they can legally consume their medication, how employers should accommodate their needs, and whether they risk law enforcement scrutiny add to the confusion and anxiety patients face daily. A significant barrier to proper legal support is the widespread lack of awareness. Many patients, healthcare professionals, and even service providers do not fully understand the legal rights and regulations governing medical cannabis use. This gap in knowledge often results in patients being misinformed or hesitant to assert their rights, while some service providers may be unwilling to support patients prescribed CBMPs simply due to uncertainty about the legal implications. Societal Stigma Despite its legalisation for medical use, cannabis continues to carry a deep-rooted stigma due to its long-standing association with recreational use and illegality. This stigma affects patients in several ways, often leading to unnecessary challenges and discrimination. One of the most significant issues is public perception. Many medical cannabis patients face judgment or misunderstanding from the public, which can result in social isolation or even outright discrimination. The misconception that all cannabis use is recreational or illicit contributes to this negative outlook, making it harder for patients to openly discuss their treatment or seek support. Employment is another area where stigma creates difficulties. Despite legal protections, employees who use medical cannabis may encounter prejudice or unfair treatment in the workplace. Employers who lack awareness or understanding of medical cannabis laws may view its use as problematic, even when it is prescribed for legitimate health conditions. This can lead to unnecessary workplace conflicts, job insecurity, or even wrongful dismissal. Stigma also extends into the healthcare system itself. Some healthcare professionals remain hesitant to prescribe cannabis-based medicinal products (CBMPs) due to lingering biases or a lack of education on the subject. This reluctance can leave patients struggling to access the treatment they need, forcing them to seek expensive private prescriptions or, in some cases, go without medication entirely. Overcoming these societal barriers requires greater public education, stronger legal protections, and a shift in cultural attitudes towards medical cannabis. Legal Support Resources For patients seeking legal assistance, several law firms and organisations specialise in areas pertinent to medical cannabis use: Organisation/Law Firm Specialties Overview Seed Our Future Legislative Research, Education, Patient Support A national campaign organisation dedicated to legislative and historical research, education through open-source reports, lectures, and articles. They provide support to UK citizens affected by unjust laws and offer assistance to medical cannabis patients facing legal and discrimination cases. Ringrose Law Medical Negligence, Discrimination, and more Offers services in medical negligence and criminal defense, pertinent to medical cannabis patients facing related legal challenges. Their team is equipped to handle cases involving medical malpractice and criminal allegations. While our current list of law firms and organisations offering legal support to medical cannabis patients in the UK is limited, we anticipate its growth as more legal professionals gain a comprehensive understanding of medical cannabis law. As awareness increases and the legal landscape evolves, we are committed to expanding our directory to better serve patients’ needs. We encourage lawyers and solicitors with relevant expertise to contact us, so we can include their services in our list and collectively enhance support for the medical cannabis community. Medical cannabis in the UK remains complex due to limited support and persistent stigma. Organisations like Seed Our Future are essential in advocating for patient rights, providing education, and challenging unjust laws. Supporting such initiatives is crucial for fostering a more informed and compassionate approach to medical cannabis use. Note: This article is for informational purposes only and should not be considered legal advice. For specific legal concerns, consult with a qualified legal professional. Medical Cannabis Employment Medical Cannabis Housing Medical Cannabis Driving Seed Our Future Ringrose Law
The post Legal Support for Medical Cannabis Patients in the UK first appeared on PatientsCann UK.
Canadian researchers have developed a unique method to allow for standardized cannabis dosing among different consumption methods. Researchers at UBC Okanagan have created an Index of Cannabis Equivalence (ICE), a unique approach to standardized cannabis dosing across different consumption methods. Published in the Journal of Psychoactive [...]
The Czech Republic is continuing to make progress on an ambitious overhaul of its drug policies, with sweeping reforms aimed at creating a regulated market for low-risk psychoactive substances and addressing long-standing issues in medical cannabis access. Starting July 2025, the sale of low-THC cannabis and [...]
UK brand, HEMPE, has secured NSF certification for its CBD gel, giving it the green-light for use among professional athletes and military personnel. The Dorset-based brand was founded by former boyband star and commando, Farard Darver, following an injury in Afghanistan. HEMPE’S CBD gel is now [...]
The airline Jet2 has apologised to a medical cannabis patient—and is said to be ‘reviewing its policies’—after their medication was confiscated on a flight from Belfast. David Toms from Belfast, who is prescribed cannabis-based medicines for chronic pain and anxiety, was flying to Antalya in Turkey [...]
Professor Terry O’Brien and his team have taken a slick approach to battling hard-to-treat epilepsy with a groundbreaking transdermal cannabidiol (CBD) gel. Here’s the scoop: After 6 months of this skin-applied magic, over half the trial participants saw their seizures sliced by more than 50%! Let’s rewind. In 2018, the U.S. FDA gave a thumbs-up to a cannabidiol […]
The post World First Australian & New Zealand Trial of Cannabidiol Transdermal Gel For Hard-to-Treat Epilepsy appeared first on I Am Billy.
Nearly 1 million Americans (many 45 and older) are battling the muscle spasms and pain that come with multiple sclerosis (MS). Turns out, up to 66% of them might be giving medical cannabis a whirl, according to a 2017 survey. And guess what? Many are dialing down on their traditional pharmaceutical MS meds. Fun fact: […]
The post How Prescription Cannabis is Shaping Up The Fight against Multiple Sclerosis appeared first on I Am Billy.
Feeling frazzled, down, or haunted by the past? Turns out, prescription cannabis might just be the unconventional companion for your mind’s rollercoaster. A recent survey found 1 in 5 older adults turning to prescription cannabis to zap the blues and calm the chaos – and over 90% claimed it worked like magic! When it comes […]
The post Prescription Cannabis: Superhero or Supervillain in Treatment of Mental Health? appeared first on I Am Billy.
Over 600,000 Americans are turning to cannabis to kiss chronic pain goodbye and science is totally backing them up. Gold-standard clinical trials (the real deal) have shown cannabis can cut pain by a whopping 40 percent for folks grappling with serious health curveballs like nerve pain (hello, diabetes), spinal cord injuries, HIV, complex regional pain […]
The post Can Prescription Cannabis Help Tame Chronic Pain? appeared first on I Am Billy.
The UK Government is being sued by a CBD business for £3.4m, in the latest major challenge to its mishandling of legal hemp. Ocean Development (Dorset) Ltd. and connected retail business CBD Flower Shop Ltd. are seeking damages from the Home Office amid allegations of ‘unlawful [...]
Wynk, a leading brand in hemp-derived THC-infused beverages, is expanding into Florida, marking an exciting milestone in its growth across the Southeast. After successful launches in Texas and Georgia, Wynk is thrilled to introduce its light, social THC seltzers to Floridians. From Jacksonville to Miami, Wynk [...]
Medical cannabis patients in the UK who receive social care packages from their local authority can apply to have their cannabis-based prescription medicines (CBPM) costs assessed as Disability Related Expenditure (DRE). If accepted, this may reduce the costs of their social care charges but does not cover costs of the cannabis prescription. Understanding Social Care Charges Under Section 14 of the Care Act 2014, local authorities can charge for social care, but they must ensure that such charges are fair and transparent. A financial assessment will determine what an individual can afford, factoring in: The assessment will disregard: Claiming CBPM Costs as DRE Patients can request that their CBPM prescription costs be considered DRE. While many councils have predefined checklists of eligible expenses, additional items may also be considered if supported by evidence. Local authorities must follow the Care Act 2014 principles, which include promoting individual wellbeing, social inclusion, and independence. If prescription costs are not accepted as DRE, it could be considered a breach of the Act, especially if this impacts a patient’s wellbeing or independence. Supporting Your Claim To claim CBPM costs as DRE, patients must provide evidence demonstrating: Unfortunately, many councils may not accept evidence from medical cannabis prescribers and instead require support from a GP and/or healthcare consultant. Patients are encouraged to request a supporting letter from their GP or healthcare consultant, detailing the necessity of CBPM and its role in reducing other treatments, such as opioids. If Your Claim Is Denied If a local authority rejects your request to classify CBPM costs as DRE, you can: The Ombudsman can recommend remedies for councils to implement. While their recommendations are not legally binding, councils rarely refuse to comply. Ensure that all medical evidence is shared with the Council and the Ombudsman. Example Case In a recent case (LGSCO reference: 24 001 331), Brighton & Hove City Council was found at fault for mishandling a social care assessment. Patients can use such precedents to support their claims. In the recent review by the Local Government and Social Care Ombudsman (LGSCO), significant concerns were raised regarding how a council handled a patient’s request to include medical cannabis costs as Disability Related Expenditure (DRE): Implications This case highlights the importance of councils adhering to their legal duty to consider all relevant evidence and provide transparent justifications for their decisions. Patients who encounter similar challenges are encouraged to challenge such decisions through formal complaints and escalate them to the Ombudsman if necessary. Key Takeaways For further guidance: Local Government and Social Care Ombudsman: https://www.lgo.org.uk/ Care Act Statutory Guidance: https://www.gov.uk/government/publications/care-act-statutory-guidance/care-and-support-statutory-guidance Medical Cannabis as Disability Related Expenditure Social Care Case Playlist by Cannabis is Medicine UK: https://www.youtube.com/playlist?list=PLmL0L5mPiFAUwDl6bG51wPOu-53MGGQMo By understanding the process and advocating for your rights, you can ensure fair consideration of your medical cannabis prescription costs within your social care assessment.
The post Claiming Social Care Support for Medical Cannabis Patients in the UK first appeared on PatientsCann UK.
Hundreds of families in the UK are giving their children illegal cannabis products due to a lack of access on the NHS, according to a new report. The research, commissioned by charity Medan Family Foundation, reveals almost 400 families are sourcing illegal cannabis products from drug [...]
Cheba Hut is teaming up with the Last Prisoner Project (LPP) for the fourth consecutive SmokeOut Injustice day. It’s all about turning tasty meals into real change and raising funds to support cannabis criminal justice reform. Last year, the team at Cheba Hut raised $133,872 for [...]
The first medical cannabis products have officially been registered in Ukraine, meaning patients should be able to access treatment in the coming weeks. Curaleaf International has successfully registered three separate oil-based products in the country, which legalised medical cannabis last August. While it will be the first [...]
Meet our main character: a 33-year-old guy who got slapped with an unexpected ADHD diagnosis later in life. His first treatment? Good old Ritalin. Things started off fine – until they didn’t. After some nasty side effects and a merry-go-round of alternative meds, our patient stumbled upon something a bit more… natural. Enter prescription cannabis. […]
The post A Dive into Medical Cannabis for Adult ADHD – A Sociological Case Report appeared first on I Am Billy.
Chronic pain – that nagging discomfort that sticks around for at least three months like an unwelcome houseguest. 40 prescription cannabis users V 161 opioid users Both opioids and prescription cannabis are the go-to contenders for pain relief. Opioids are like the heavyweight champs – quick and effective at knocking out pain, whether it’s […]
The post Prescription Cannabis V Opioids in Chronic Pain – Who’s Got the Holistic Edge? appeared first on I Am Billy.
A new study has investigated changes in opioid use in US states which have passed medical and recreational cannabis laws. The study, led by Columbia University Mailman School of Public Health, found no changes in opioid outcomes among the general population following the states’ passage of [...]
At PatientsCann UK, we are deeply concerned by Network Rail’s recently issued safety advice (NRA24-13), which imposes a blanket ban
The post Network Rail’s Medical Cannabis Policy: A Cause for Concern first appeared on PatientsCann UK.
A trial went down at the San Carlo Hospital’s pain therapy unit in Potenza, Italy, using prescription cannabis in patients with fibromyalgia. The Scoop; Patients with fibromyalgia saw their pain intensity (on the trusty NRS scale) nosedive from an eye-watering 8 to a manageable 4 over just 6 months. Things didn’t just stop at pain […]
The post Can Prescription Cannabis Help Tame Fibro Pain? appeared first on I Am Billy.
The authors of a new Canadian study have called for increased public funding to protect the ‘scientific integrity’ of cannabis research and reduce reliance on industry sponsorship. Research led by the Centre for Addiction and Mental Health (CAMH) in Canada, sheds light on the ethical complexities [...]
Inflammatory bowel disease (IBD) patients in the UK have reported improvements in their condition following treatment with medical cannabis. According to observational data published in the journal Expert Review of Gastroenterology & Hepatology, medical cannabis treatment was associated with sustained improvements in health-related quality of life [...]
New preliminary research highlights the potential of Ayurvedic medicine combined with medical cannabis as an alternative treatment for menstrual cramps. Results from a Phase 1 clinical trial have found ‘strong preliminary evidence’ to support the safety and efficacy of a new patent-pending formulation in the management [...]
Thousands of French medical cannabis patients have been given a temporary reprieve, enabling them to continue accessing their treatment for another six months. Amid the continued political chaos in the country, participants in France’s medical cannabis ‘experiment,’ which is now entering its fifth year, faced an [...]
Written by Ben Stevens and Sarah Sinclair. You can read Part 1 here. Growing demand for medical cannabis across Europe Medical cannabis demand across Europe has seen substantial growth, particularly following the regulatory changes in Germany. Ukraine’s Health Minister, Viktor Liashko, visited Germany this year as [...]
Written by Ben Stevens and Sarah Sinclair. 2024 has been a dramatic year for the global cannabis industry, seeing both historic steps forward and concerning regressions in both attitudes and policy. It was a year dominated by elections, with around half of the world’s population [...]
In a new study researchers explored whether CBD can reduce scan-related anxiety in patients with advanced breast cancer. The findings showed that while CBD did not significantly change scan-related anxiety when compared to a placebo, it was safe and resulted in significantly lower overall anxiety levels [...]
Via Business of Cannabis French patient associations have warned that medical cannabis patients could soon face a disruption in treatment as its long-running experiment comes to an end with no next steps in place. The French Society for the Study and Treatment of Pain (SFETD) issued [...]
From April 2025, Dutch coffee shops will only be permitted to sell regulated cannabis products, as the next phase of the country’s adult-use pilot gets underway. One year on from the launch of the Netherlands’ Closed Coffee Shop Chain Experiment, regulators have set a fixed date [...]
Jazz Pharmaceuticals has shared new data to support the efficacy of Epidiolex in patients with tuberous sclerosis complex (TSC). Research shared at the American Epilepsy Society (AES) 2024 Annual Meeting held from 6-10 December in Los Angeles, California supports the use of Epidiolex in the treatment [...]
MAPS (Multidisciplinary Association for Psychedelic Studies) has secured FDA clearance to conduct a clinical trial examining the use of smoked cannabis for the treatment of PTSD symptoms among veterans. After three years of negotiation, the FDA has given MAPS the green light to carry out a [...]
Via Business of Cannabis In a long-awaited and major step forward for the UK’s CBD sector, the regulator has announced a new roadmap that could see the first products given official approval by Spring next year. While this announcement comes nearly seven years after the novel [...]
Thousands more doctors in the Czech Republic will soon be permitted to prescribe medical cannabis under a new decree published by the Ministry of Health. From April 2025, the country’s 5,000 general practitioners will be permitted to prescribe medical cannabis to patients with chronic pain, following [...]
Via Business of Cannabis UK-based biotech firm Ananda Developments has solidified its position as a driving force in clinical cannabis research in Europe, announcing the launch of two more major trials using its proprietary compounds. Last month, Business of Cannabis reported that two long-awaited NHS clinical trials to [...]
Researchers from the Centre for Reproductive Health at the University of Edinburgh have co-authored a new review paper highlighting the potential of CBD in the treatment of endometriosis. The new paper, published in the top-ranking journal Trends in Pharmacological Science (TIPS), finds that CBD is a [...]
A newly-obtained report by France’s Directorate General of Health (DGS) evaluating the impact of the medical cannabis pilot, recommended the roll out of a temporary regulatory framework last year. The Union of Industrialists for the Valorization of Hemp Extracts (UIVEC) in France says the report, dated [...]
Representatives from five European countries, as well as the European Union Drug Agency (EUDA), met in Germany last week to discuss the regulation of cannabis for non-medical purposes. European leaders from Luxembourg, Malta, the Netherlands and Czech Republic attended an international ministerial exchange in Germany to [...]
Via Business of Cannabis Denmark’s six-year medical cannabis pilot scheme could soon be expanded into a fully legalised market, following a surprise announcement from the government last week. The Danish pilot scheme has been running since 2018, and has continued to expand in both scope and [...]
Luxembourg is set to restrict access to high-THC cannabis flower on prescription from next year, as part of longer term plans to phase out flower-based products altogether. As of January 2025, patients in Luxembourg will no longer be able to access cannabis flower containing high levels [...]
New research has found no association between long-term cannabis use and cognitive decline in later life. Longitudinal data published in the journal Brain and Behavior, found no significant harmful effects of cannabis use on age-related cognitive decline. Researchers in Denmark examined the relationship between lifetime cannabis [...]
Copyright © 2020 – 2025 | The Cannabis Pages | All Rights Reserved | Important Notice | The Cannabis Pages “TCP” is an information resource for medical cannabis patients and prescribers. Nothing on the site should be construed as a promotion or inducement. TCP does not promote any product or represent that the products mentioned on TCP’s website are treatment for any kind of medical condition. TCP cannot guarantee that information provided is error-free or complete and is not responsible for the quality of the information provided by users. Cannabis is an unlicensed medication which can only be administered under the supervision of a licensed physician.
